Commercialization of hemostatic agents: Progress and Challenges

Bleeding and leakage of body fluids is a serious risk within the clinic for many surgery and trauma patients. While hemostatic agents are designed to prevent fluid loss quickly, slow response and high cost can limit the effectiveness and access to existing solutions. Arch Therapeutics, a Wellesley, MA-based medical device company, has stepped in to address this need with the AC5 Surgical Hemostatic Device. Currently in preclinical development, AC5 is designed to achieve hemostasis when used during both laparoscopic and open surgical procedures. Come learn more about the development of this technology and the company founding from Dr. Terrence Norchi, the company’s CEO and Founder.

norchiTerrence W. Norchi, MD, MBA, is the co-founder, President, and Chief Executive Officer of Arch Therapeutics. He brings invaluable experience and knowledge to Arch’s core technology and proposed product candidates as a result of his first-hand experience with the development of that technology from the research laboratory to its current stage of development. Prior to Arch, Dr. Norchi was portfolio manager of one of the world’s largest healthcare mutual funds and pharmaceutical analyst at Putnam Investments.  His investing experience as a former public company analyst and a portfolio manager provides further insights and value as the company advances toward commercialization.  Prior to that he served as the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management, and as a sell-side analyst covering non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York City.